Adaptive Biotherapeutic Agent Delivery Platform

A next-generation, implantable biotherapeutic agent delivery system that integrates self-healing, nanoscale, porous matrices with artificial intelligence and machine learning algorithms to optimize therapeutic outcomes.

The original patent's implantable cellular and biotherapeutic agent delivery canister, while innovative, has limitations in terms of adaptability to changing host environments and lack of real-time optimization. The new inventive concept addresses these limitations by incorporating adaptive nanophase morphologies, bioresorbable canisters, and AI-driven optimization.

The new inventive concept comprises a modular, implantable device featuring multiple, interconnected nanophase modules, each with unique morphology and composition tailored to specific disease states. The nanophase tubular structure is designed to adapt to changes in the host environment, releasing therapeutic metabolites in a biologically relevant environment. The system integrates artificial intelligence and machine learning algorithms to optimize therapeutic outcomes in real-time.

The new claims introduce several non-obvious features, including self-healing, nanoscale, porous matrices, bioresorbable canisters, and AI-driven optimization, which significantly depart from the original patent's design and operation.

Alternative embodiments may include varying the nanophase morphology and composition to target specific disease states, incorporating additional sensors or actuators to enhance real-time optimization, or developing miniaturized versions of the device for targeted delivery.

The new inventive concept has significant commercial potential in the fields of regenerative medicine, immunotherapy, and personalized medicine, with potential applications in treating chronic diseases such as autoimmune disorders, cancer, and cardiovascular disease.